More News

22 Jun 2021 ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
17 Jun 2021 FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
17 Jun 2021 Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat
17 Jun 2021 Debiopharm and Ubix Therapeutics Launch Research to Develop a New Anti-Cancer Modality - Antibody Degraducer® Conjugates
17 Jun 2021 Lumen Bioscience and Novo Nordisk Enter into Research Collaboration to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease
15 Jun 2021 CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
10 Jun 2021 Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors
10 Jun 2021 Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders
04 Jun 2021 Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology
03 Jun 2021 Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer
03 Jun 2021 Proteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca
02 Jun 2021 MorphoSys to Acquire Constellation Pharmaceuticals
01 Jun 2021 Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure
27 May 2021 eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies
26 May 2021 Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
26 May 2021 Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
25 May 2021 Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
20 May 2021 BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
19 May 2021 Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb
18 May 2021 BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
14 May 2021 Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
12 May 2021 Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
11 May 2021 Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
11 May 2021 Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
05 May 2021 Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top